Pediatric Oncology

Santhosh Upadhyaya, MD, neuro-oncologist, St. Jude Children’s Research Hospital, discusses the design of the 10-year-long SJYC07 trial.

Michael Link, MD, a 2018 Giant of Cancer Care® in Pediatric Oncology, discusses the exciting progress being made for various pediatric tumors.

Sarah K. Tasian, MD, an attending physician and assistant professor of pediatrics in the Division of Oncology at Children’s Hospital of Philadelphia, discusses the challenges in treating pediatric patients with Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL).

Early identification of inherited predisposition to forms of myelodysplastic syndrome and acute myeloid leukemia in pediatric patients can assist in treatment decisions and selection for familial stem cell transplant.

Following survival improvements in the field of adolescents and young adults with acute lymphoblastic leukemia, researchers must turn their focus to lowering toxicity, and delivering treatment to high-risk subgroups, among others.

Matthew Ladra, MD, MPH, discusses the treatment of patients with esthesioneuroblastoma, emphasizing the need for collaboration in this rare malignancy.

Zhaoming Wang, PhD, discusses the first assessment of the joint effects of rare and common genetic variations in survivors of childhood cancers.

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the use of immunotherapy in the treatment of pediatric patients with cancer.

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for the treatment of pediatric and adult patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Technological advancements in molecular tumor profiling are starting to make a difference in pediatric oncology, where the search for new therapies is challenging and frustrating.

Joseph V. Simone, MD, is best known for leading the research efforts that resulted in the first curative combination treatment for certain pediatric patients with acute lymphoid leukemia. Under his leadership, the St. Jude Children’s Research Hospital in Memphis, Tennessee, was designated the first and only National Cancer Institute cancer center dedicated to children. He was honored in the Pediatric Oncology category with a 2017 Giants of Cancer Care® award.

The FDA has accepted a supplemental biologics license application for dasatinib for use in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses a genomic analysis of breast cancer risk in pediatric cancer survivors.

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the process of T-cell differentiation in pediatric solid tumors.

Ami Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.

Elissa Engel, MD, pediatric resident, University of South Florida, discusses the future of eltrombopag (Promacta) in HIV-related thrombocytopenia.

Rosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with sarcoma.

Sixty percent of adult survivors of pediatric CNS tumors do not achieve full functional and social independence, according to results from a study conducted by researchers at St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center.

James I. Geller, MD, describes the ongoing work in pediatric patients with rare rhabdoid tumors.

Kristopher R. Bosse, MD, discusses how D3-GPC2-PBD could impact pediatric neuroblastoma.

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the impact of T-cell differentiation and exhaustion in pediatric cancer.

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1-negative tumors.

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses integrating palliative care into the treatment of pediatric oncology.

Brian D. Crompton, MD, provides insight on the debate of liquid versus tissue biopsies, particularly in the setting of pediatric patients with sarcomas.

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer.

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors.

Ami Vijay Desai, MD, discusses the ideal patient population for entrectinib and what the future could hold for the agent.

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses clinical needs in pediatric patients with bone sarcoma.